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T
his supplement contains 9 articles that arose from a
Department of Veterans Affairs sponsored State of the Art
(SOTA) conference “Managing Complexity in Chronic Care.” It
is appropriate that these articles appear in the Journal of
General Internal Medicine. Advocates for general internal
medicine as a specialty often mention the care of complex
chronically ill patients as a special competency of General
Internists.
1 Moreover, the Society of General Internal Medicine
and its members have been leaders in recognizing and
addressing the research and policy importance of this large
patient population.
2 The editors of JGIM believe that this
supplement provides critical early exposure for research topics
that will appeal to funders such as the VA, other federal
agencies, and foundations like the Robert Wood Johnson
Foundation who wish to encourage research regarding the
care for this challenging, but growing population.
During the months spent overseeing and contributing to the
peer review of the articles included in this supplement, we were
struck that some of our usual editorial criteria were difficult to
apply. It appeared to us that the science of studying the
chronic care of complex patients required significant changes
in our concept of “important research results.” Three of the
articles, by Luck et al, Sevick et al and Vogeli et al, present
reviews of the literature. We were relieved to see that these
authors also struggled to identify research that met traditional
standards for rigorous methodology. It was interesting that
Luck et al, who examine the business case for improving care,
were able to find considerable information on patients with
single complex chronic diseases, but had much less informa-
tion regarding persons with multiple conditions, one of the
features that distinguishes many complex patients. Young
et al, whose literature review examined chronic illness care in
general, although with a focus on the complex patient, had an
easier time discovering high-quality relevant research.
One likely contributor to the dearth of high-quality studies
of the care of complex patients is the lack of agreement on
what constitutes a complex patient. Although the explicit
conference focus on “chronic care” excluded the obviously
complex patient developing multiorgan system failure during
an intensive care unit for sepsis, the definition of complexity
remained unclear. It seems likely that the authors of these
manuscripts would differ in how to rank the importance of the
number of chronic conditions versus their long-term morbidity
implications versus the complexity of their current manage-
ment. It seems that almost all complexity literature would
identify a patient with depression, diabetes with microalbumi-
nuria, osteoarthritis, and hypertension as complex. However,
many VA primary care providers would note that almost all
their patients are complex by this criterion! If asked to identify
the factors that identify their “more complex” patients, we
suspect that many clinicians would answer “it depends”—a
hard standard to apply when analyzing large populations,
although an experienced provider might be able to pick out
such a patient after just one visit.
With this in mind, we were glad to see Safford et al present
one theoretical construct of complexity, an important exercise
that will need to be repeated by other researchers. Similarly, we
were pleased to note that the 3 articles focused on presenting
original data took different approaches to defining complexity,
providing the reader and future researchers ample food for
thought regarding the difficulty of the issue. We hope that the
followinginsightsgleanedfromourstrugglewithevaluating this
diverse set of manuscripts will provide some guidance to future
editors, scientific reviewers, and funding agencies, as well as
persons trying to clarify how best to study this complex topic.
First, we were struck by the broad variety of papers we saw.
The diversity of methods and topics was daunting and exciting.
In the same conference, one set of authors tried to develop a
conceptual model needed to define the field, whereas others
looked at applying systems engineering approaches to that
field. A third paper presented the business case for developing
new approaches to treating the target population, something
typically left for last in American medicine. Whereas this
diversity of topics in part reflects the Department of Veteran’s
Affairs dual focus on methodologic rigor and practical applica-
tion, we also believe that the topic’s breadth and importance
attract researchers from many disciplines who bring many
perspectives about what is important.
Second, we noted that both generalizability and internal
validity are likely to be threatened in studies of complex
patients. Generalizability has been an issue in the interpreta-
tion of study results for many years: all health care providers,
except those practicing in one Massachusetts town, have had
to wonder whether the Framingham data could be applied to
their own patients. However, it is particularly hard to decide
whether the results seen in a researcher’s set of complex
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being seen by a practicing Internist seeking to practice
evidence-based medicine, or even to the group of complex
patients served by a given health care system.
Internal validity is enhanced when a study is adequately
powered to minimize type I and II errors, clearly defines the
study intervention(s), and measures outcomes in a clear,
reproducible fashion. Unfortunately, complexity makes it hard
to do each of these. It is difficult to assemble a population that
is large enough to identify anything but the strongest relation-
ships. In this supplement, we see this tension as researchers
must decide whether sharing several common chronic condi-
tions is enough to define a meaningful population even when
many members of that population have other, more important
conditions that were not common enough to warrant inclusion
in the definition. Interventions that are of interest in a diverse
population of complex patients are likely to be multifaceted
interventions, which may need to be delivered one way to some
complex patients and in a different way to others. Quality of life
and functional outcomes that are increasingly staples of health
services research are harder to interpret and utilize in the
same way among persons with differing types of complexity.
Third, we thought that the counterintuitive results of Lee
et al, might provide particularly important methodologic
lessons. These investigators used the number of conditions
defined by ICD9-CM diagnosis codes to measure increasing
complexity and found that the addition of certain conditions
appeared to decrease mortality, although overall, the more
conditions that were present, the greater the mortality. Over 3
decades of work with claims data has taught the Health
Services Research community that incentives inherent in the
process by which claims are created can generate spurious
associations.
3,4 Thus, because more “optional” diagnoses may
be coded for patients who are less severely ill, osteoarthritis
(one of the protective conditions) may simply be a marker for
limited severity of illness. However, itis unclear that the effects
seen by Lee et al are associations created by the method, or if
greater complexity may lead to more encounters with the
health care system, proving greater opportunities for appro-
priate preventive services to be delivered. As the research
presented in this supplement was conducted in the VA, the
largest health care provider in the United States, and used its
robust electronic medical system, it is not surprising that
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such results clearly call for confirmation in research using
alternate methods.
Because of the importance of understanding these
approaches, we encouraged these authors to describe their
methods in detail so that other researchers could use or
modify them as they see fit. It will be as important to clearly
state how one defined complexity as it is to explicitly state
whether one considers hypertension present above 160/95,
140/90, or 125/75 mmHg. One interesting next step may be to
use different definitions of complexity within a project, in a
type of sensitivity analysis. It may be that treating mental
health issues as a separate complexity axis should be an
important part of all studies of complexity. Similarly, one
wonders if existing readily available measures of socioeconom-
ic context (ZIP code level variables for example) should be
routinely added to counts of comorbid conditions. When
considering clinical comorbidities, researchers will have simi-
lar tough decisions. For example, they will need to decide
whether they need to go beyond tumor (yes/no) and metastatic
(yes/no) used by the Charlson comorbidity scale when decid-
ing how much added detail about severity adds to counts of
diseases.
5 We suspect that in most cases the limited clinical
detail included in the ICD9-CM coding system will feel very
limiting indeed. Moreover, even when added levels of detail are
present, it is likely that the accuracy of coding will decrease as
the level of detail increases.
Related to this concern is the observation that although
Safford et al point out that complexity has many components
or axes, the papers that present empiric data tend to focus
simply on burden of illness. This is also seen in the classic
references showing, for example, that the 23% of Medicare
patients with 5 or more chronic conditions account for more
than two thirds of program expenditures.
6 As claims provide
more data on medical than social contributors to complexity,
the emphasis on the former is in part a response to data
availability. However, it will be necessary to develop databases
that include measures of these other axes. It will take
significant reorientation of funders to provide resources for
this new kind of data collection. In turn, researchers will need
to take advantage of existing datasets that do combine social
and medical data to a greater extent—Medicare’s Current
Beneficiary Survey comes to mind.
7
Finally, we noted that the problems we are seeing with
complex patients are not novel. Rather, they are just more
complex!! A recent supplement to the American Journal of
Medicine identified heterogeneity of treatment effects as an
important issue. One article focused on differences in response
to hypertension treatment within and between randomized
trials.
8 The authors note that patients with different age and
genetic background may respond differently to the same
treatment. This problem seems quite tractable when one
compares this to determining whether a specific strategy can
improve the outcomes of patients afflicted with “complexity.” In
an editorial accompanying the supplement, Sheldon Green-
field adds illness severity, concomitant medications and
comorbidities, treatment setting, and diet as potential influ-
ences on treatment response.
9 Each of these is likely to differ
among complex patients.
In addition, practical issues may make it problematic to
fund research that addresses complexity. The lack of a specific
disease focus will limit access to the increasingly large pool of
money that the National Institutes of Health (NIH) is directing
at studying “real life” disease problems. Just as quality
improvement researchers found it hard to craft practical
projects sufficiently rigorous to be competitive for VA Health
Services Research and Development (HSRD) or Agency for
Healthcare Research and Quality (AHRQ) funding, complexity
researchers may have difficulty convincing these same study
sections that they have been able to adequately define popula-
tions, interventions, and outcomes in a way that reliably
answers a set of clear hypotheses. Funding agencies and
research agencies need to find ways to deal with this type of
research. Within VA, this may be possible through the Quality
Enhancement Research Initiative (QUERI) mechanism as well
as the recently convened Chronic Disease Management study
section and HSRD solicitation regarding this important area of
research. Within AHRQ and the NIH, specific dollars have been
set aside to fund novel, high-priority areas like developing
380 Whittle and Bosworh: Studying Complexity is Complex JGIMpractice-based research networks, expanding the reach of
health information technology or fostering community-based
participatory research. Foundations have often been key
funders of the first researchers in novel areas. We hope this
supplement raises the profile of complexity research so that
these key constituencies recognize its importance.
Corresponding Author: Jeff Whittle, MD, MPH; Primary Care
Division, Clement J. Zablocki VA Medical Center, Milwaukee, WI,
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